Hypothalamic obesity
Rhythm’s Oral MC4R Agonist Bivamelagon Shows Promising Results in Rare Obesity Type
Rhythm Pharmaceuticals; oral weight-loss drug; bivamelagon; MC4R agonist; Phase 2 trial; hypothalamic obesity; BMI reduction; clinical trial results